Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27376906 | 0.84 | SRC (0.45) | GAANPC1ALDH1A1HSP90AA1MAPT | |
| SCHEMBL2129737 | 0.82 | KDM4E (0.41) | ALDH1A1HSP90AA1KDM4EUSP2TAAR1 | |
| SCHEMBL11153594 | 0.82 | NPC1 (0.60) | GAANPC1ALDH1A1HSP90AA1MAPT | |
| SCHEMBL2472257 | 0.82 | ALDH1A1 (0.43) | ALDH1A1KDM4EUSP2SRCSLC22A12 | |
| SCHEMBL29328225 | 0.80 | P2RX3 (0.42) | GAANPC1ALDH1A1HSP90AA1KDM4E | |
| SCHEMBL26561752 | 0.80 | SRC (0.50) | HSP90AA1SRCABL1BCRHSP90AB1 | |
| Chloroneb SCHEMBL22739 | 0.79 | GAA (0.64) | GAANPC1ALDH1A1HSP90AA1MAPT | |
| SCHEMBL145418 | 0.79 | TRPV4 (0.54) | ALDH1A1MAPK1SLC22A12MAOBTRPV4 | |
| SCHEMBL24252866 | 0.79 | SRC (0.43) | ALDH1A1HSP90AA1KDM4EUSP2SRC | |
| SCHEMBL15797427 | 0.79 | GAA (0.60) | GAANPC1ALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4288516-A | Polyester resin containing magnetic toner material and process for its use in flash fuser | XEROX CORPORATION (US) | 1981-09-08 | — | — | US | claimed |
| EP-0033248-A1 | Magnetic toner and method for developing using same | XEROX CORPORATION (US) | 1981-08-05 | — | — | EP | claimed |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Oppilan Pharma Limited (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | Oppilan Pharma Limited (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20210163485-A1 | Heterocyclic Compounds for the Treatment of Disease | OPPILAN PHARMA LTD (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20200325135-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10683291-B2 | Heterocyclic compounds for the treatment of disease | OPPILAN PHARMA LTD. (GB) | 2020-06-16 | — | — | US | disclosed |
| US-20200071327-A1 | Prodrugs for the Treatment of Disease | OPPILAN PHARMA LTD (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20190241556-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD. (GB) | 2019-08-08 | — | — | US | disclosed |
| WO-2017083756-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD. (US) | 2017-05-18 | — | — | WO | disclosed |
| EP-2370438-A1 | IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | Exelixis, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-4377581-A | ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4351940-A | Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4287341-A | USEFUL AS ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1981-09-01 | — | — | US | disclosed |
| EP-0028473-A1 | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them | PFIZER INC. (US) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325135-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | GAA 69/4885NPC1 144/4885ALDH1A1 562/4885 |
| US-20210163485-A1 | Heterocyclic Compounds for the Treatment of Disease | VHL, FH, TPMT | GAA 70/4885NPC1 144/4885ALDH1A1 545/4885 |
| US-20200071327-A1 | Prodrugs for the Treatment of Disease | DPYD, PAICS, TYMP | GAA 179/4885NPC1 649/4885ALDH1A1 322/4885 |
| US-20190241556-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | GAA 69/4885NPC1 144/4885ALDH1A1 562/4885 |
| US-10683291-B2 | Heterocyclic compounds for the treatment of disease | VHL, FH, TPMT | GAA 69/4885NPC1 144/4885ALDH1A1 562/4885 |
| US-20230339944-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | GAA 69/4885NPC1 144/4885ALDH1A1 562/4885 |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | GAA 4315/4885NPC1 241/4885ALDH1A1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.